Collegium Pharmaceutical Inc
NASDAQ:COLL

Watchlist Manager
Collegium Pharmaceutical Inc Logo
Collegium Pharmaceutical Inc
NASDAQ:COLL
Watchlist
Price: 31.19 USD 1.3% Market Closed
Market Cap: 1B USD
Have any thoughts about
Collegium Pharmaceutical Inc?
Write Note

Collegium Pharmaceutical Inc
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Collegium Pharmaceutical Inc
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Collegium Pharmaceutical Inc
NASDAQ:COLL
Long-Term Debt
$802.6m
CAGR 3-Years
55%
CAGR 5-Years
148%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Long-Term Debt
$31.3B
CAGR 3-Years
1%
CAGR 5-Years
3%
CAGR 10-Years
9%
Bristol-Myers Squibb Co
NYSE:BMY
Long-Term Debt
$48.7B
CAGR 3-Years
7%
CAGR 5-Years
15%
CAGR 10-Years
21%
Pfizer Inc
NYSE:PFE
Long-Term Debt
$57.5B
CAGR 3-Years
17%
CAGR 5-Years
10%
CAGR 10-Years
6%
Merck & Co Inc
NYSE:MRK
Long-Term Debt
$35B
CAGR 3-Years
15%
CAGR 5-Years
9%
CAGR 10-Years
7%
Eli Lilly and Co
NYSE:LLY
Long-Term Debt
$29B
CAGR 3-Years
23%
CAGR 5-Years
16%
CAGR 10-Years
19%
No Stocks Found

Collegium Pharmaceutical Inc
Glance View

Market Cap
1B USD
Industry
Pharmaceuticals

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The company is headquartered in Stoughton, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2015-05-07. Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. The firm's product portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR (Nucynta Products), which are extended-release (ER) and immediate-release (IR) formulations of tapentadol. Xtampza ER is formulated using its abuse-deterrent technology platform, DETERx. Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.

COLL Intrinsic Value
47.46 USD
Undervaluation 34%
Intrinsic Value
Price

See Also

What is Collegium Pharmaceutical Inc's Long-Term Debt?
Long-Term Debt
802.6m USD

Based on the financial report for Sep 30, 2024, Collegium Pharmaceutical Inc's Long-Term Debt amounts to 802.6m USD.

What is Collegium Pharmaceutical Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
148%

Over the last year, the Long-Term Debt growth was 52%. The average annual Long-Term Debt growth rates for Collegium Pharmaceutical Inc have been 55% over the past three years , 148% over the past five years .

Back to Top